Summary
This report presents findings from ICON plc's 2025 global biotech survey, which includes insights from over 260 biotech professionals and venture capital executives across various regions, including the US, Europe, Asia-Pacific, and the Middle East. The first part of the survey focuses on global biotech trends, highlighting the resilience of the industry, particularly in APAC markets, and the emergence of China as a significant player in global innovation. The report indicates that 92% of leaders expect to meet their next investment milestone, with a notable increase in R&D spending planned by three out of four biotechs. The second part of the survey specifically examines trends within the Chinese biotech market, revealing challenges such as funding and drug development complexities. It also notes that while global therapeutic focus areas have shifted, cell therapy and microbiome therapies dominate pipelines across regions. The report emphasizes the growing importance of digital technologies, particularly AI, in accelerating R&D processes.
